Skip to content

Frailty and negative consequences in adults hospitalized for COVID-19

Frailty and adverse outcomes in adults hospitalized for COVID-19 - CO-FRAIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-7w5zhr
Enrollment
Unknown
Registered
2020-07-30
Start date
2020-03-30
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus infection, unspecified

Interventions

Cohort study investigating approximately 2000 individuals aged 50 years or older admitted for COVID-19 to the Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP) in
Other
V03.175.500

Sponsors

Hospital das Clínicas da Faculdade de Medicina da USP
Lead Sponsor
Hospital das Clínicas da Faculdade de Medicina da USP
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: We will include consecutive patients hospitalized for COVID-19, between March and July 2020. Patients are screened for eligbility at admission according to the following criteria: age greater than or equal to 50 years; suspected (signs and symptoms suggestive of the disease without confirmatory tests), probable (signs and symptoms suggestive of the disease with compatible tomographic image) or confirmed COVID-19 (agent detected by laboratory test), as per WHO guidelines; informed consent for participation in the study.

Exclusion criteria

Exclusion criteria: We will exclude patients for whom the diagnosis of COVID-19 is discarded during follow-up until the end of hospitalization (absence of a compatible tomographic image, negative virus detection tests, and alternative diagnosis more likely).

Design outcomes

Primary

MeasureTime frame
Hospital death, and death at 30 days, 6 months, and 1 year. In-hospital death is evaluated by review of hospital records. Death at 30 days, 6 months and 1 year will be evaluated by telephone interviews. We expect a 10% difference in mortality between frail vs. robust individuals.

Secondary

MeasureTime frame
Length of hospital stay (days); patients in the upper tertile will be classified as prolonged hospital stay, assessed by medical record review. A higher risk of prolonged hospitalization is expected in frail individuals, measured by multivariate regression models (relative risk greater than 1).;Occurrence of Acute Respiratory Distress Syndrome (ARDS), assessed by reviewing medical record diagnoses. A higher risk of ARDS is expected in frail individuals, measured by multivariate regression models (relative risk greater than 1).;Need for mechanical ventilation (MV), assessed by review of medical records. A higher risk of MV is expected in frail individuals, measured by multivariate regression models (relative risk greater than 1).;Admission to the intensive care unit (ICU), assessed by review of medical records. A higher risk of admission to the ICU is expected in frail individuals, measured by multivariate regression models (relative risk greater than 1).;Length of ICU stay (days), assessed by review of medical records. A longer ICU stay is expected in frail individuals, measured by multivariate regression models (relative risk greater than 1).;Occurrence of delirium during hospital stay (yes or no), assessed by review of medical records. A higher risk of delirium is expected in older individuals, as measured by multivariate regression models (relative risk greater than 1).;Functional decline at 30 days, 6 months and 1 year after discharge, assessed by the BOMFAQ scale criteria. A higher risk is expected in older and frail individuals, as measured by multivariate regression models (relative risk greater than 1).;Frailty at 30 days, 6 months and 1 year post-discharge, assessed by the FRAIL scale and Clinical Frailty Scale (CFS) criteria. A higher risk is expected in older individuals, measured by multivariate regression models (relative risk greater than 1).;Health care utilization (admission to emergency units or hospitalization) within 30 days, 6 months, and 1 year

Countries

Brazil

Contacts

Public ContactMárlon;Thiago Aliberti;Avelino-Silva

Hospital das Clínicas da Faculdade de Medicina da USP;Hospital das Clínicas da Faculdade de Medicina da USP

maliberti@usp.br;thiago.avelino@usp.br+55-11-26618116;+55-11-26618116

Outcome results

None listed

Source: REBEC (via WHO ICTRP)